Grifols | GRFS - Assets


Grifols reported EUR23.15B in Assets for its fiscal quarter ending in December of 2025.





Assets Change Date
Alaunos Therapeutics USD 1.88M 1.08M Mar/2026
Arca Biopharma USD 1.14B 634.91M Jun/2026
aTyr Pharma USD 69.82M 9.83M Jun/2026
Bio Path USD 677K 13K Mar/2026
Brainstorm Cell Therapeutics USD 788K 33K Jun/2026
Capricor Therapeutics USD 368.74M 42.45M Jun/2026
Cara Therapeutics USD 25.82M 6.26M Mar/2026
GlaxoSmithKline GBP 61.74B 1.13B Jun/2026
Grifols EUR 23.15B 142.7M Dec/2025
Immunic USD 189.74M 165.69M Mar/2026
Minerva Neurosciences USD 97.97M 69.88M Dec/2025
Nektar Therapeutics USD 763.27M 482.86M Mar/2026
Sangamo BioSciences USD 97.56M 11.39M Jun/2025
TherapeuticsMD USD 40.13M 1.96M Jun/2024